Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

301 results about "Anticancer treatment" patented technology

Anticancer, or antineoplastic, drugs are used to treat malignancies, or cancerous growths. Drug therapy may be used alone, or in combination with other treatments such as surgery or radiation therapy.

Immune humanized liver cancer patient-derived xenotransplantation mouse model and construction method and application thereof

The invention relates to an immune humanized liver cancer patient-sourced xenotransplantation mouse model and a construction method and application thereof, and belongs to the technical field of medical research and biologication.The immune humanized liver cancer PDX model is innovatively constructed by optimizing transplantation of tumor tissues and introducing and screening immune cells, and the model has the advantages of being high in specificity, high in sensitivity and high in reliability. The defects of a traditional PDX model in immune system and immunotherapy evaluation are overcome. The model has tumor characteristics of liver cancer patients and a functional human immune system, has reliable immune response and anti-cancer treatment evaluation capability, and provides scientific and reliable model support for research and screening of novel liver cancer immunotherapy.
Owner:ZHUJIANG HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY

Combination of POLQ inhibitor compound and Anti-cancer therapeutic agent or radiotherapy

Provided is a combination comprising a compound of formula (A) as a POLQ inhibitor or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof and at least one anti-cancer therapeutic agent or radiotherapy, which combination is used for preventing or treating cancers, and the use of the combination in the prevention or treatment of cancers. The structure of the compound of formula (A) is as shown below.
Owner:NANJING ZAIMING PHARM CO LTD

Porous silicate and / or aluminosilicate matrix / cerium oxide nanoparticle nanocarrier for combination anti-cancer therapeutic and antioxidant delivery

A nanomedicinal composition comprising a nanocarrier and a pharmaceutical agent mixture including an anti-cancer therapeutic and an antioxidant. The nanocarrier contains a porous silicate and / or aluminosilicate matrix and cerium oxide nanoparticles in the pores of the porous silicate and / or aluminosilicate matrix. The pharmaceutical agent mixture is disposed in the pores and / or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating breast cancer.
Owner:IMAM ABDULRAHMAN BIN FAISAL UNIV

Intelligent anti-cancer science popularization content recommendation method and system based on patient big data

The invention discloses an intelligent anti-cancer science popularization content recommendation method and system based on patient big data, and the method comprises the following steps: collecting patient data, including static data and behavior data, the behavior data including search history, click record, browsing duration, activity participation record, and reading content; extracting user features from the patient data, and generating a user portrait; anti-cancer popular science contents in the platform are collected, and labels are added to the popular science anti-cancer contents by using a natural language processing technology and a machine learning algorithm; constructing a content recommendation engine for dynamically matching the user portrait with the tag; according to the matching result of the content recommendation engine, generating a personalized content recommendation list in combination with the current anti-cancer treatment stage of the patient; and transmitting the recommended content by using multiple channels according to the content recommendation list. According to the method, the user portrait is constructed through the multi-dimensional data of the patient, so that the pertinence and adaptability of recommendation can be effectively improved.
Owner:XIAMEN COBBLESTONE NETWORK TECH CO LTD

Oncolytic virus compositions and methods for the treatment of cancer

Provided herein, inter alia, are oncolytic viruses that express recombinant proteins having bispecific activity. The recombinant proteins include a first fusion protein comprising a first Fc domain covalently linked to a chemokine domain, and a second Fc fusion protein comprising a second Fc domain covalently linked to an anticancer therapeutic antibody domain. The recombinant proteins and oncolytic viruses provided herein are contemplated to be effective for the treatment of cancer, particularly by trafficking immune cells to the tumor microenvironment.
Owner:CITY OF HOPE

Compositions and methods for multiplex base editing in hematopoietic cells

When a cancer patient is administered an anti-cancer therapy targeting a lineage specific cell-surface antigen (e.g., CD33 (Siglec-3), CLL-1, CD123, CD327 (Siglec-6), and / or CD312 (EMR2)), e.g., in the form of an immunotherapeutic agent, the therapy can deplete not only cancer cells expressing the lineage-specific cell-surface antigen, but also noncancerous cells expressing the lineage-specific cell-surface antigen in an “on-target, off tumor” effect. This disclosure provides, e.g., novel cells having a modification (e.g., insertion or deletion) in an endogenous lineage-specific cell-surface antigen (e.g., CD33 (Siglec-3), CLL-1, CD123, CD327 (Siglec-6), and / or CD312 (EMR2)) gene. The disclosure also provides compositions, e.g., gRNAs, that can be used to make such a modification.
Owner:SYZYGYMED INC

Methods of treating cancer and predicting responsiveness to therapy by assessing ZNFX1 exression

The present invention pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, and monitoring therapy can be used for prognostic (predictive) purposes to thereby treat an individual having cancer. Accordingly, one aspect of the present invention relates to methods of treating a subject having cancer by determining the amount and / or activity level of ZNFX1 in the context of a biological sample (e.g., blood, serum, cells, or tissue) to thereby determine whether an individual afflicted with a cancer is likely to respond to anti-cancer therapy, whether in an original or recurrent cancer.
Owner:UNIV OF MARYLAND +3

Polypeptide-drug conjugate that binds to il4ra and use thereof

The present invention relates to a polypeptide-drug conjugate that binds to IL4Ra and a use thereof, and provides: a polypeptide comprising a ligand that specifically binds to IL4Ra and a temperature-responsive disordered domain; and a polypeptide-drug conjugate in which a cytotoxic drug is bound to the polypeptide. More specifically, the polypeptide, in which an IL4RA-binding ligand and a temperature-responsive disordered domain are repetitively linked, exhibits high selectivity in binding to IL4Ra, and the polypeptide-drug conjugate, in which a cytotoxic drug is bound to the polypeptide, demonstrates significantly enhanced cancer cell-killing efficacy and anti-tumor activity compared to unbound drugs or conventional anticancer agents, and has been confirmed to suppress drug resistance in cancer cells that are resistant to the anticancer agent temozolomide. Accordingly, the polypeptide-drug conjugate can be provided as an effective anticancer therapeutic agent for the treatment of tumors overexpressing IL4Ra and as a pharmaceutical composition for inhibiting drug resistance in cancer cells exhibiting resistance to anticancer drugs.
Owner:EXCELLAMOL CO LTD

Extracellular vesicles from microalgae, their biodistribution upon administration, and uses

Provided are compositions containing extracellular vesicles from microalgae (MEVs) that are loaded with bioactive cargo. The MEVs are formulated and administered by a variety of routes of administration and have a variety of applications as therapeutics, including as vaccines, as anti-cancer therapeutics, as therapeutics for psychiatric diseases, disorders, and conditions, and as diagnostics, and other such uses.
Owner:AGS THERAPEUTICS SAS

mmWave array and implanted susceptors for hyperthermia-based anti-cancer treatments

Methods and systems for hyperthermia-based anti-cancer treatments are disclosed herein. One disclosed system for hyperthermia-based anti-cancer treatments includes an array of millimeter wave amplifier integrated circuits having an output energy, one or more medical grade implantable susceptors, and a beam steering controller for the array of millimeter wave amplifier integrated circuits that is configured to steer the output energy of the array of millimeter wave amplifier integrated circuits into the one or more medical grade implantable susceptors.
Owner:MMTRON INC

Composition for Anti-cancer treatment comprising immunogenic tumor-derived extracellular vesicles using an endoplasmic reticulum stress inducer and method for producing the same

The present invention relates to a composition for anti-cancer treatment, the composition including immunogenic tumor-derived extracellular vesicles using an endoplasmic reticulum stress inducer, and a method for producing the same. The composition according to the present invention includes extracellular vesicles in which tumor immune-activating protein is increased and immune-suppressive protein is decreased so that immunogenicity is enhanced, and thus can be used as a pharmaceutical composition or a food composition for anti-cancer treatment.
Owner:RES & BUSINESS FOUND SUNGKYUNKWAN UNIV

Method for hyperthermially treating a cancer

A nanomedicinal composition comprising a nanocarrier and a pharmaceutical agent mixture comprising an anti-cancer therapeutic and an antioxidant. The nanocarrier comprises a porous silicate matrix and particles of a magnetic ferrite disposed in the pores of the porous silicate matrix. The pharmaceutical agent mixture is disposed in the pores and / or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating breast cancer.
Owner:IMAM ABDULRAHMAN BIN FAISAL UNIV

Anti-trop2 antibodies in immunosuppressed subjects

It forms an object of the present invention a composition comprising the 4F6 anti-Trop-2 antibody and / or its conjugates for use in the treatment of a Trop-2-expressing tumors in a subject, wherein said subject is immunosuppressed by anticancer treatments, such as chemotherapy or radiotherapy.
Owner:ADRIATX SRL

Engineering bacterium photo-thermal hydrogel smearing equipment

The utility model discloses engineering bacteria photo-thermal hydrogel smearing equipment which comprises a fixing frame, a smearing mechanism, a transmission mechanism and a uniform smearing part, the transmission mechanism is arranged on the fixing frame and can drive base layer cloth to transmit, the smearing mechanism can coat hydrogel and attach the hydrogel to the base layer cloth, and the uniform smearing part is located on one side of the smearing mechanism. The smearing mechanism can evenly smear hydrogel smeared on base layer cloth, the even smearing component comprises an even smearing plate and a lifting component, a gap exists between the even smearing plate and the conveying mechanism, and the lifting component can adjust the size of the gap between the even smearing plate and the conveying mechanism. The prepared hydrogel can be attached to the position needing to be treated, for example, the hydrogel can be applied to the fields of skin wounds and anti-cancer treatment.
Owner:陈钰荣

Modified mitochondria comprising prodrug invertase and uses thereof

The present invention relates to a modified mitochondrial comprising, on the outer membrane of the mitochondrial, an antibody that binds to a cancer cell-specific protein and a cytosine deaminase. It is proved that when the mitochondria and 5-FC are jointly used for treating a pancreatic cancer cell line, the cytotoxicity induced by 5-FC treatment is remarkably enhanced. The effect is proved as follows: 5-FC is converted into 5-FU by cytosine deaminase expressed on a mitochondrial outer membrane, so that pancreatic cancer cells are induced to generate apoptosis. Therefore, the modified mitochondria according to the present invention can be effectively used in anticancer therapy using 5-FC as an anticancer agent.
Owner:PAEAN BIOTECH

Heparanase-neutralizing A54 monoclonal antibody

The present invention relates to an heparanase-binding and heparanase-neutralizing monoclonal antibody (IgG-1 mAb A54), including its epitope (HBD-II) and mode of interaction with heparanase, pharmaceutical composition comprising same, and uses thereof e.g. for inhibiting or treating a disease or disorder associated with heparanase activity, including but not limited to cancer, inflammation, viral infection, diabetes and related complications. The present invention further provides combinatorial cancer therapies, comprising the heparanase-neutralizing mAb and an additional anti-cancer treatment such as chemotherapy or radiation.
Owner:TECHNION RES & DEV FOUND LTD +1

Combination therapy of anticancer treatment with toll-like receptor 7 or 8 agonist having active site temporarily inactivated for cancer treatment

The present invention relates to a method for treating cancer, in which the anticancer effect is significantly enhanced by using a Toll-like receptor 7 or 8 agonist having the active site temporarily inactivated. The present invention provides a pharmaceutical composition for combination administration for preventing or treating cancer, comprising, as an active ingredient, a Toll-like receptor 7 or 8 agonist in which the active site is bound to cholesterol via a cleavable linker to be temporarily inactivated, wherein the pharmaceutical composition is administered after 1-20 days following anticancer treatment.
Owner:PROGENEER

Nuclear transport inhibitors for Anti-cancer combination therapy

A combination for use in treating cancer is provided. The combination comprises a therapeutically effective amount of an inhibitor of nuclear import protein Karyopherin Beta 1 (Kpnβ1) such as the substituted pyrrolo[2,3-b]quinoxalines of Formula I and a therapeutically effective amount of an inhibitor of nuclear export protein Chromosome Maintenance 1 (Crm1) such as the hydrazide- containing compounds of Formula II. The combination therapy provides an enhanced anti-cancer therapeutic effect compared to the effect of each of the nuclear transport inhibitors administered alone.
Owner:UNIVERSITY OF CAPE TOWN

Application of glehnia littoralis in preparation of medicine

The invention relates to the technical field of application of glehnia littoralis, in particular to application of glehnia littoralis in preparation of drugs, and discloses new application of glehnia littoralis in preparation of drugs for preventing postoperative recurrence and metastasis of tumors, and the glehnia littoralis is applied to preparation of drugs for preventing postoperative recurrence and metastasis of tumors under the concentration of not causing cytotoxicity and toxic and side effects. Through multiple key steps of intervening tumor metastasis, including inhibition of adhesion of circulating tumor cells on vascular endothelial cells, inhibition of EMT transformation of the circulating tumor cells, inhibition of trans-endothelial migration of the circulating tumor cells and the like, the effect of preventing tumor metastasis or treating tumors is achieved, and meanwhile, the activity of immune cells is improved; the traditional Chinese medicine composition has the advantages of being capable of enhancing the killing ability of immune cells to circulating tumor cells, prolonging the lifetime, having extremely high safety, and solving the problems that the immune system and the rehabilitation ability are damaged in anti-cancer treatment by traditional medicines, the traditional cancer prevention and treatment strategy is limited and the like.
Owner:福州海洋研究院

IL-8 inihibitors for use in the treatment of some urological disorders

The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1 / CXCR2 receptor inhibitors, useful in the treatment and / or prevention of interstitial cystitis / painful bladder syndrome (IC / PBS) and / or over active bladder (OAB), also including IC / PBS and / or OAB induced by anticancer therapy. Methods of treatment and / or prevention, combinations and kits comprising said IL-8 inhibitors are also covered therein.
Owner:DOMPE FARMACEUTICI SPA

Preparation method and application of active oxygen response type artificial ion channel

The application provides an active oxygen response type artificial ion channel, and a structural general formula is as follows: the application is activated by high level ROS in cancer cells, the activated channel promotes the synergistic transmembrane transmission of H + and Cl ‑ ions, thereby realizing specific anticancer treatment, the synthetic route of the application is green, simple, efficient, raw materials are easy to obtain, and can be used for synthesis of similar compounds.
Owner:XIAMEN UNIV +1

Sortilin inhibitors for treatment of patients with functional neuroendocrine tumors

PCT designated stage expiredWO2024245719A1Antibody ingredientsAntineoplastic agentsSerotoninCarcinoid tumour
The present invention relates to the field of anti-cancer therapies, more specifically to therapies with the aim of improving the health of patients suffering from functional neuroendocrine tumors (NETs) or functional neuroendocrine neoplasms (NENs). In particular, the invention discloses the use of sortilin inhibitors for treating a condition associated with the release of an endocrine and / or a paracrine factor such as serotonin by a functional neuroendocrine neoplasm in a subject, e.g., carcinoid syndrome, carcinoid heart disease, and / or carcinoid crisis. The sortilin inhibitor can be provided in a pharmaceutical composition and may be a small molecule inhibitor having a molecular weight of 800 daltons or less, an anti-sortilin antibody, an inhibitory nucleic acid, a proteolysis-targeting chimera, a peptide-based inhibitor or a combination thereof.
Owner:CHARITE UNIVS MEDIZIN BERLIN

Peptide binding to mesothelin, and use thereof

PendingEP4477660A1Peptide/protein ingredientsPeptidesPeptide displayCancer cell
The present invention relates to a peptide binding to mesothelin, and use thereof, wherein the peptide of the present invention specifically binds to mesothelin and inhibits same, and thus the effect of inhibiting the migration and metastasis of cancer cells is exhibited. It has been identified that the peptide of the present invention was selected, using a phage peptide display technology, as one type of peptide that easily binds to cells in which human mesothelin is highly expressed, and thus the peptide binds to mesothelin and inhibits the migration of cancer cells. The peptide of the present invention is relatively stable in serum, and thus exhibits high potential as an anti-cancer therapeutic agent for inhibiting metastasis according to cancer progression and migration in the future, an anti-cancer drug delivery probe, and a cancer diagnostic probe.
Owner:KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND

Methods of treating cancer with inhibitors of fn14

Disclosed herein are methods for treating cancer with inhibitors of FN14 (e.g., Compound 1), or pharmaceutically acceptable salts thereof. The disclosure further provides methods of treating cancer with inhibitors of FN14 or pharmaceutically acceptable salts thereof, in combination with additional anti-cancer therapeutics (e.g., a kinase inhibitor).
Owner:VIVIA ONCOLOGY INC

Chelating Agents for Use in Cancer Therapy

The invention provides a chelating agent for use in a method of treating cancer in a subject, wherein said cancer has a resistance to an anti-cancer therapeutic agent. Further, the invention provides a chelating agent for use in a method of sensitizing a subject for an anti-cancer treatment and / or counteracting a resistance to an anti-cancer therapeutic agent, wherein the method restores or re-activates a tumor suppressor protein function that preferably was impaired due to aberrant tumor suppressor protein folding. The invention also provides a pharmaceutical composition comprising a 2,3-Dimercapto-1-propanesulfonic acid (DMPS) or DMSA, preferably miaDMSA, and a pharmaceutically acceptable excipient; wherein the DMPS is present in a dose of 40-12000 mg.
Owner:PLECO THERAPEUTICS BV

Anti-trop2 antibodies for use in treating immunosuppressed subjects

It forms an object of the present invention a composition comprising the 4F6 anti-Trop-2 antibody and / or its conjugates for use in the treatment of a Trop-2-expressing tumors in a subject, wherein said subject is immunosuppressed by anticancer treatments, such as chemotherapy or radiotherapy.
Owner:ADRIATX SRL

Near-infrared two-region luminous multi-resonance hybrid four-free-radical molecular compound as well as preparation and application thereof

The invention belongs to the field of organic photoelectric materials, and particularly discloses a near-infrared two-region (NIR-II) multi-resonance hybrid four-free-radical molecule and preparation and application thereof, the structure of the molecule is as follows: in addition, the research on free radical materials in the aspect of NIR-II fluorescence imaging guided photo-thermal anticancer treatment is still limited, and the molecule has a wide application prospect. And the material is mainly concentrated on a double-free-radical material. A chain D-A-A-D type organic four-free-radical compound is designed and synthesized on the basis of a classical Cichibabin skeleton, the near-infrared two-region light-emitting multiple resonance hybrid four-free-radical molecular compound is high in stability and has the near-infrared two-region photoluminescence property, the near-infrared two-region light-emitting multiple resonance hybrid four-free-radical molecular compound is applied to research in biological photo-thermal anticancer treatment, and the near-infrared two-region light-emitting multiple resonance hybrid four-free-radical molecular compound has a wide application prospect. And the photo-thermal conversion efficiency of 87% is shown.
Owner:HUNAN UNIV